SCHEMBL522158

SCHEMBL522158

CSc1ncc2ccc(-c3cccc(COC(C)(C)C)c3)n2n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 5/20 0.36
PTK2 Q05397 3/20 0.36
INSR P06213 1/20 0.36
ALK Q9UM73 1/20 0.36
SLC5A1 P13866 2/20 0.35
DYRK1A Q13627 2/20 0.35
PRMT5 O14744 1/20 0.33
WDR77 Q9BQA1 1/20 0.33
FYN P06241 5/20 0.33
KDM4E B2RXH2 3/20 0.33
ALDH1A1 P00352 3/20 0.33
HPGD P15428 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
DYRK3 O43781 1/20 0.32
CCNT1 O60563 1/20 0.32
CCNA2 P20248 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL521095 0.86 JAK2 (0.35) JAK2PTK2INSRALKDYRK1A
SCHEMBL521288 0.84 SLC5A1 (0.38) JAK2PTK2INSRALKSLC5A1
SCHEMBL521476 0.83 FYN (0.48) JAK2PTK2FYN
SCHEMBL521284 0.81 FYN (0.38) JAK2PTK2INSRALKSLC5A1
SCHEMBL521018 0.78 MEN1 (0.40) JAK2PTK2INSRALKFYN
SCHEMBL522199 0.78 DYRK3 (0.44) JAK2PTK2INSRALKDYRK1A
SCHEMBL520494 0.77 DYRK3 (0.45) JAK2PTK2INSRALKDYRK1A
SCHEMBL519714 0.76 KDM4E (0.52) JAK2PTK2INSRALKDYRK1A
SCHEMBL521096 0.74 DYRK1A (0.37) JAK2PTK2INSRALKDYRK1A
SCHEMBL16530364 0.74 JAK2 (0.37) JAK2PTK2INSRALKDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376491-B1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON INC (US) 2015-03-04 EP disclosed
US-8471005-B2 Pyrrolotriazines as ALK and JAK2 inhibitors CEPHALON, INC. (US) 2013-06-25 US disclosed
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2012-02-02 US disclosed
EP-2376491-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS Cephalon, Inc. (US) 2011-10-19 EP disclosed
WO-2010071885-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS JAK2, ALK, ABL1 JAK2 1/4885PTK2 592/4885INSR 1738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.